Immuneering Corp Cl A (IMRX)

$6.69 -0.05 (-0.74%)
Market Cap 435.20M
Revenue (ttm) 0.00
Net Income (ttm) -61.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 589,100
Avg Vol 2,008,206
Day's Range N/A - N/A
Shares Out 64.57M
Stochastic %K 20%
Beta 0.46
Analysts Strong Sell
Price Target $16.83

Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Cor...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 500 8080
Address:
245 Main Street, Second Floor, Cambridge, United States
bemore
bemore Dec. 5 at 1:10 AM
$IMRX from ymb, according to 13F & 13G filing, as of 6-30-25, there is only 39 institutions owned IMRX. as of 9-30-25 , there is 75 institutions owmed IMRX. That is very unusual for the # of institutions to increse holding of IMRX almost by 93% in 3 months.
1 · Reply
Iightning
Iightning Dec. 4 at 11:58 PM
1ightning® Premium Options Alert (Actionable) Ticker: $IMRX Contract: Dec 19 $5C Entry: 1.45 Exit: 2.02 Return: +39.14% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
BiotechBonesaw
BiotechBonesaw Dec. 4 at 8:58 PM
$VKTX $QNTM $IMRX $DRUG get ready 😳 https://www.investors.com/news/technology/medical-stocks-biotech-stocks-research-stocks-fda-clinical-trials/
0 · Reply
Eruption
Eruption Dec. 4 at 4:28 PM
$IMRX More great results. This will be a huge drug IMO. Keep it going Dr. Ben!
1 · Reply
gvariant
gvariant Dec. 4 at 4:09 PM
$IMRX
0 · Reply
Uatu616
Uatu616 Dec. 4 at 3:25 PM
$IMRX there should be news today, correct?
2 · Reply
Captenotwo
Captenotwo Dec. 3 at 7:31 PM
$IMRX was holding 15,000 of capr for about 5 years. Started buying it at $1.14 Sold some today at $38 I missed the dip here but as you can see I am patient and you should be too. Bought more IMRX at $6.66 Cheers Cap
4 · Reply
essiepaul
essiepaul Dec. 3 at 3:02 PM
$IMRX wtf with this bs
1 · Reply
kubota2323
kubota2323 Dec. 3 at 2:39 PM
$IMRX look at shorts in $CAPR 14 million. Lol
0 · Reply
JH2500
JH2500 Dec. 3 at 1:09 PM
$IMRX: In dager of breaking Support here. Fully expect Short Algo Bots to get to work again today. They play the long game and wear Retail buyers out. That is what is happening here. Shorts want $IRMX to head lower and they almost always get their way.
1 · Reply
Latest News on IMRX
Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 8:00 AM EST - 9 days ago

Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference

Immuneering Corporation (IMRX) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 9:11 PM EST - 22 days ago

Immuneering Corporation (IMRX) Q3 2025 Earnings Call Transcript

Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates

Nov 12, 2025, 4:05 PM EST - 22 days ago

Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates

Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025

Nov 4, 2025, 4:05 PM EST - 4 weeks ago

Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025

Immuneering Corporation - Special Call

Sep 29, 2025, 4:37 PM EDT - 2 months ago

Immuneering Corporation - Special Call

Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

Sep 26, 2025, 4:01 PM EDT - 2 months ago

Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

Immuneering: Positive Pancreatic Cancer Data Atebimetinib Leads To Q4 2025 Catalyst

Sep 25, 2025, 2:19 PM EDT - 2 months ago

Immuneering: Positive Pancreatic Cancer Data Atebimetinib Leads To Q4 2025 Catalyst

Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi

Sep 25, 2025, 12:08 AM EDT - 2 months ago

Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi

Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi

Sep 24, 2025, 4:05 PM EDT - 2 months ago

Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi

Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Sep 24, 2025, 4:01 PM EDT - 2 months ago

Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Immuneering Appoints Dr. Thomas Schall as Chairman of the Board

Sep 16, 2025, 7:00 AM EDT - 2 months ago

Immuneering Appoints Dr. Thomas Schall as Chairman of the Board

Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25

Sep 10, 2025, 7:00 AM EDT - 3 months ago

Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25

Immuneering Announces Closing of $25 Million Private Placement

Aug 26, 2025, 4:05 PM EDT - 3 months ago

Immuneering Announces Closing of $25 Million Private Placement

Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib

Aug 25, 2025, 8:00 AM EDT - 3 months ago

Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib

LLY

Immuneering Announces $25 Million Private Placement

Aug 21, 2025, 8:00 AM EDT - 3 months ago

Immuneering Announces $25 Million Private Placement

Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 13, 2025, 4:05 PM EDT - 4 months ago

Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates

Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib

Jul 9, 2025, 8:00 AM EDT - 5 months ago

Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib

Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients

Jun 17, 2025, 6:00 AM EDT - 6 months ago

Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025

Jun 16, 2025, 8:00 AM EDT - 6 months ago

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025

Immuneering to Present at the Jefferies Global Healthcare Conference

May 29, 2025, 8:00 AM EDT - 6 months ago

Immuneering to Present at the Jefferies Global Healthcare Conference

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates

May 5, 2025, 4:05 PM EDT - 7 months ago

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference

Apr 2, 2025, 8:00 AM EDT - 8 months ago

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference

Immuneering Corporation Announces Grant of Inducement Award

Mar 21, 2025, 4:30 PM EDT - 9 months ago

Immuneering Corporation Announces Grant of Inducement Award

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 20, 2025, 4:05 PM EDT - 9 months ago

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

Mar 20, 2025, 7:00 AM EDT - 9 months ago

Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 3, 2025, 4:05 PM EST - 10 months ago

Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Why Is Immuneering Stock Trading Higher On Tuesday?

Jan 7, 2025, 9:28 AM EST - 11 months ago

Why Is Immuneering Stock Trading Higher On Tuesday?

Immuneering Launches Pancreatic Cancer Advisory Board

Dec 19, 2024, 8:00 AM EST - 1 year ago

Immuneering Launches Pancreatic Cancer Advisory Board

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

Dec 13, 2024, 2:10 PM EST - 1 year ago

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

FOLD

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

Dec 12, 2024, 8:00 AM EST - 1 year ago

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

Nov 27, 2024, 8:00 AM EST - 1 year ago

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 13, 2024, 4:05 PM EST - 1 year ago

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Sep 12, 2024, 4:05 PM EDT - 1 year ago

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

May 7, 2024, 4:05 PM EDT - 1 year ago

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

Immuneering Recognizes Melanoma Awareness Month

May 6, 2024, 4:30 PM EDT - 1 year ago

Immuneering Recognizes Melanoma Awareness Month

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

Apr 9, 2024, 12:00 PM EDT - 1 year ago

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Apr 3, 2024, 4:05 PM EDT - 1 year ago

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

Mar 27, 2024, 8:00 AM EDT - 1 year ago

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone

Mar 19, 2024, 2:19 AM EDT - 1 year ago

Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone

Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors

Mar 14, 2024, 7:00 AM EDT - 1 year ago

Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors

Immuneering Appoints Thomas J. Schall, Ph.D.

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Immuneering Appoints Thomas J. Schall, Ph.D.

Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors

Mar 11, 2024, 8:00 AM EDT - 1 year ago

Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

Mar 6, 2024, 8:00 AM EST - 1 year ago

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

BLRX CADL ONCY

Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024

Mar 5, 2024, 5:00 PM EST - 1 year ago

Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024

Immuneering to Participate in the Cowen 44th Annual Health Care Conference

Mar 4, 2024, 8:00 AM EST - 1 year ago

Immuneering to Participate in the Cowen 44th Annual Health Care Conference

Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Mar 1, 2024, 8:00 AM EST - 1 year ago

Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

Feb 20, 2024, 8:00 AM EST - 1 year ago

Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

Immuneering Announces Participation in February Investor Conferences

Feb 1, 2024, 8:00 AM EST - 2 years ago

Immuneering Announces Participation in February Investor Conferences

bemore
bemore Dec. 5 at 1:10 AM
$IMRX from ymb, according to 13F & 13G filing, as of 6-30-25, there is only 39 institutions owned IMRX. as of 9-30-25 , there is 75 institutions owmed IMRX. That is very unusual for the # of institutions to increse holding of IMRX almost by 93% in 3 months.
1 · Reply
Iightning
Iightning Dec. 4 at 11:58 PM
1ightning® Premium Options Alert (Actionable) Ticker: $IMRX Contract: Dec 19 $5C Entry: 1.45 Exit: 2.02 Return: +39.14% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
BiotechBonesaw
BiotechBonesaw Dec. 4 at 8:58 PM
$VKTX $QNTM $IMRX $DRUG get ready 😳 https://www.investors.com/news/technology/medical-stocks-biotech-stocks-research-stocks-fda-clinical-trials/
0 · Reply
Eruption
Eruption Dec. 4 at 4:28 PM
$IMRX More great results. This will be a huge drug IMO. Keep it going Dr. Ben!
1 · Reply
gvariant
gvariant Dec. 4 at 4:09 PM
$IMRX
0 · Reply
Uatu616
Uatu616 Dec. 4 at 3:25 PM
$IMRX there should be news today, correct?
2 · Reply
Captenotwo
Captenotwo Dec. 3 at 7:31 PM
$IMRX was holding 15,000 of capr for about 5 years. Started buying it at $1.14 Sold some today at $38 I missed the dip here but as you can see I am patient and you should be too. Bought more IMRX at $6.66 Cheers Cap
4 · Reply
essiepaul
essiepaul Dec. 3 at 3:02 PM
$IMRX wtf with this bs
1 · Reply
kubota2323
kubota2323 Dec. 3 at 2:39 PM
$IMRX look at shorts in $CAPR 14 million. Lol
0 · Reply
JH2500
JH2500 Dec. 3 at 1:09 PM
$IMRX: In dager of breaking Support here. Fully expect Short Algo Bots to get to work again today. They play the long game and wear Retail buyers out. That is what is happening here. Shorts want $IRMX to head lower and they almost always get their way.
1 · Reply
natureman67
natureman67 Dec. 3 at 2:03 AM
$IMRX Stock market is pretty much un-investible now. Shorts and robots are killing all innovative US companies. Only biotechs left will be run by China.
1 · Reply
Mwd04
Mwd04 Dec. 2 at 11:38 PM
$IMRX bought more
0 · Reply
bioland
bioland Dec. 2 at 9:06 PM
$IMRX So many people trade bios....that shouldn't trade bios...
0 · Reply
THowellThe3rd
THowellThe3rd Dec. 2 at 9:02 PM
$IMRX Market Makers and big money out Stop hunting and looking for weak stomach retail investors. Hold your shares and ignore the market noise.
1 · Reply
rickahuna
rickahuna Dec. 2 at 8:56 PM
$IMRX But hey you invest in the company..."Reported Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP" Median survival is 9.3 months, so they have an impressive drug which after 2b, the share price now will be nothing if the reports are again extraordinary.
0 · Reply
rickahuna
rickahuna Dec. 2 at 8:50 PM
$IMRX I bet Sanofi wished they waited a day or two also "Sanofi purchased 2,708,559 shares of Immuneering’s Class A common stock at a purchase price of $9.23 per share"
1 · Reply
Captenotwo
Captenotwo Dec. 2 at 6:44 PM
$IMRX Wish I’d waiting a day. Cap
1 · Reply
SpittingImage
SpittingImage Dec. 2 at 4:54 PM
$IMRX headed to $6 😕
1 · Reply
JH2500
JH2500 Dec. 2 at 4:50 PM
$IMRX: These Short Algo Bots. Horrible people running these things. Systematically target all these small caps over $5. No chance against these things.
0 · Reply
AlwaysBullish99
AlwaysBullish99 Dec. 2 at 4:36 PM
$IMRX Heavy shorting started early today. Still bullish as this is a long hold.
0 · Reply
JH2500
JH2500 Dec. 2 at 4:29 PM
$IMRX: Short Algo Bot again today. Hitting right under every ask. Only a machine can do that. Major money backing this. Rats all the way around but highly effective. If they target a small cap its over.
0 · Reply
OptimistJP
OptimistJP Dec. 2 at 3:33 PM
$IMRX what is the fascination with MMs and shorts beating this stock down? Praying for fire and brimstone on their heads.
0 · Reply